Gemcitabine and Device occlusion - a phase IV clinical study of FDA data

Summary:

Device occlusion is reported as a side effect among people who take Gemcitabine (gemcitabine), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Abraxane, and have Pancreatic carcinoma.

The phase IV clinical study analyzes which people have Device occlusion when taking Gemcitabine. It is created by eHealthMe based on reports of 31,291 people who have side effects when taking Gemcitabine from the FDA, and is updated regularly.

What is Gemcitabine?

Gemcitabine has active ingredients of gemcitabine. eHealthMe is studying from 31,337 Gemcitabine users. Check the latest studies of Gemcitabine.

What is Device occlusion?

Device occlusion is found to be associated with 591 drugs and 512 conditions by eHealthMe. Check the latest studies of Device occlusion.

On Jul, 15, 2026

31,291 people reported to have side effects when taking Gemcitabine.
Among them, 39 people (0.12%) have Device occlusion.

Could Gemcitabine cause Device occlusion?

Among these 39 people:

How long have people been on Gemcitabine when they have Device occlusion? *

What is the gender of people who have Device occlusion when taking Gemcitabine? *

female: 45.71 %
male: 54.29 %

What is the age of people who have Device occlusion when taking Gemcitabine? *

What are other drugs people take besides Gemcitabine? *

Abraxane: 9 people, 23.08%
Pantoprazole: 5 people, 12.82%
Erlotinib Hydrochloride: 3 people, 7.69%
Melatonin: 3 people, 7.69%
Ondansetron Hydrochloride: 3 people, 7.69%
Cisplatin: 3 people, 7.69%
Lovenox: 2 people, 5.13%
Ketoprofen: 2 people, 5.13%
Vicodin: 2 people, 5.13%
Hydrocodone Bitartrate And Acetaminophen: 2 people, 5.13%

What are other side effects people have besides Device occlusion? *

Thrombocytopenia (decrease of platelets in blood): 8 people, 20.51%
Cholangitis (infection of the bile duct): 7 people, 17.95%
Sepsis (a severe blood infection that can lead to organ failure and death): 6 people, 15.38%
Fever: 6 people, 15.38%
Pneumonia: 5 people, 12.82%
Aspartate Aminotransferase Increased: 5 people, 12.82%
Alanine Aminotransferase Increased: 5 people, 12.82%
Pain: 4 people, 10.26%
Diarrhea: 4 people, 10.26%
Blood Bilirubin Increased: 4 people, 10.26%

What are the existing conditions these people have? *

Pancreatic Carcinoma (pancreatic cancer): 17 people, 43.59%
Pancreatic Carcinoma Metastatic (pancreatic cancer- metastatic): 9 people, 23.08%
Adenocarcinoma Pancreas (cancer of pancreas): 5 people, 12.82%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 3 people, 7.69%
Pain: 2 people, 5.13%
Lung Cancer - Non-Small Cell (lung cancer): 2 people, 5.13%
Oral Herpes (viral infection of mouth): 1 person, 2.56%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 1 person, 2.56%
Neoplasm Malignant (cancer tumour): 1 person, 2.56%
Nausea (feeling of having an urge to vomit): 1 person, 2.56%

* Approximation only. Some reports may have incomplete information.

Do you take Gemcitabine and have Device occlusion?

- Check whether Device occlusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gemcitabine:

Gemcitabine (31,337 reports)

Device occlusion treatments and more:

Device occlusion (13,307 reports)

Browse all side effects of Gemcitabine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Device occlusion:

Device occlusion (591 drugs)

Browse all the conditions that are associated with Device occlusion:

Device occlusion (512 conditions)

Related publications that referenced our studies

Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .
Alam, S., Illo, C., Ma, Y. T., & Punia, P. , "Gemcitabine-induced cardiotoxicity in patients receiving adjuvant chemotherapy for pancreatic cancer: a case series", Case reports in oncology, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gemcitabine (the active ingredients of Gemcitabine) and Gemcitabine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.